Exact Mass: 619.105784

Exact Mass Matches: 619.105784

Found 24 metabolites which its exact mass value is equals to given mass value 619.105784, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

gdp-D-mannuronate

GDP-D-mannuronate; GDP-D-mannuronic acid

C16H23N5O17P2 (619.0564168000001)


   

ADP-D-Glycero-D-manno-heptose

ADP-D-glycero-beta-D-manno-heptose

C17H27N5O16P2 (619.0928002)


   

ADP-L-glycero-D-manno-heptose

ADP-L-glycero-beta-D-manno-heptose

C17H27N5O16P2 (619.0928002)


An ADP-glycero-D-manno-heptose having L-glycero-configuration at the 6-position of the heptose portion.

   

Relcovaptan (SR-49059)

1-[5-Chloro-3-(2-chlorophenyl)-1-(3,4-dimethoxybenzenesulphonyl)-3-hydroxy-2,3-dihydro-1H-indole-2-carbonyl]pyrrolidine-2-carboximidic acid

C28H27Cl2N3O7S (619.0946692)


   
   

NO-Indomethacin

N-acetyl-D-cysteine-1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid, 4-(nitrooxy)butyl ester

C28H30ClN3O9S (619.13912)


   

CHLORODICARBONYL[1-(I-PROPYLAMINO)-2,3,4,5-TETRAPHENYLCYCLOPENTADIENYL]RUTHENIUM(II)

CHLORODICARBONYL[1-(I-PROPYLAMINO)-2,3,4,5-TETRAPHENYLCYCLOPENTADIENYL]RUTHENIUM(II)

C34H28ClNO2Ru (619.0851858000001)


   

NKP608

NKP608

C31H24ClF6N3O2 (619.1461146)


NKP608 is a non-peptidic derivative of 4-aminopiperidine which acts as a selective, specific and potent antagonist at the neurokinin-1 (NK-1) receptor both in vitro(IC50=2.6 nM) and in vivo. IC50 value: 2.6 nM Target: NK-1 receptor In vitro, the binding of NKP608 to bovine retina was characterized by an IC50 of 2.6+/-0.4 nM, whereas the compound's affinity to other receptor binding sites, including NK-2 and NK-3, was much lower. Species differences in IC(50) values with NKP608 were less pronounced than with previously described NK-1 receptor antagonists, being 13+/-2 and 27+/-2 nM in gerbil midbrain and rat striatum, respectively. In vivo, using the hind foot thumping model in gerbils, NKP608 exhibited a potent NK-1 antagonistic activity following oral administration (ID(50)=0.23 mg/kg; 2 h pretreatment), supporting a central activity of NKP608. NKP608 may prove a useful anxiolytic compound.

   

Relcovaptan

Relcovaptan

C28H27Cl2N3O7S (619.0946692)


D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C2180 - Vasopressin Antagonist D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors

   
   

Glesatinib

Glesatinib

C31H27F2N5O3S2 (619.1523296000001)


C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor

   

1,2,3-Tri-O-benzoyl-α-L-fucopyranose, Trichloroacetimidate

1,2,3-Tri-O-benzoyl-α-L-fucopyranose, Trichloroacetimidate

C29H24Cl3NO8 (619.0567434000001)


   
   

[[(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(2-hydroxyethyl)oxan-2-yl] hydrogen phosphate

[[(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(2-hydroxyethyl)oxan-2-yl] hydrogen phosphate

C17H27N5O16P2 (619.0928002)


   

[[(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5S,6S)-3,4,5-trihydroxy-6-(2-hydroxyethyl)oxan-2-yl] hydrogen phosphate

[[(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5S,6S)-3,4,5-trihydroxy-6-(2-hydroxyethyl)oxan-2-yl] hydrogen phosphate

C17H27N5O16P2 (619.0928002)


   

[[(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5S,6R)-3,4,5-trihydroxy-6-(2-hydroxyethyl)oxan-2-yl] hydrogen phosphate

[[(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5S,6R)-3,4,5-trihydroxy-6-(2-hydroxyethyl)oxan-2-yl] hydrogen phosphate

C17H27N5O16P2 (619.0928002)


   

[[[(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] (2S,3R,4R,5R)-2,3,4,5-tetrahydroxy-6-oxohexanoate

[[[(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] (2S,3R,4R,5R)-2,3,4,5-tetrahydroxy-6-oxohexanoate

C16H23N5O17P2 (619.0564168000001)


   
   

[[[5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] 2,3,4,5-tetrahydroxy-6-oxohexanoate

[[[5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] 2,3,4,5-tetrahydroxy-6-oxohexanoate

C16H23N5O17P2 (619.0564168000001)


   

ADP-L-glycero-beta-D-manno-heptose

ADP-L-glycero-beta-D-manno-heptose

C17H27N5O16P2 (619.0928002)


An ADP-L-glycero-D-manno-heptose having beta-configuration at the anomeric centre of the heptose.

   
   

ADP-D-glycero-beta-D-manno-heptose

ADP-D-glycero-beta-D-manno-heptose

C17H27N5O16P2 (619.0928002)


The beta-anomer of ADP-D-glycero-D-manno-heptose.

   

GDP-6-deoxy-D-manno-heptose

GDP-6-deoxy-D-manno-heptose

C17H27N5O16P2 (619.0928002)


   

Glutaminase-IN-1

Glutaminase-IN-1

C26H24F3N7O3Se (619.105784)


Glutaminase-IN-1 (CB839 derivative), a CB839 derivative, is an allosteric inhibitor of 1,3,4-selenadiazole-containing kidney-type glutaminase (KGA), with an IC50 of 1 nM. Glutaminase-IN-1 (CB839 derivative) shows improved cellular uptake and antitumor activity.